AI in Healthcare 2025

Tern plc

The year 2025 marked a significant shift in the integration of artificial intelligence into healthcare, as the technology moved from experimental phases into active use across clinical and commercial settings. AI, once viewed as a long-term prospect, began delivering practical benefits, with healthcare organisations adopting it to streamline operations, enhance patient communication and improve medical outcomes.

Throughout the year, generative AI was deployed more widely in hospitals, clinics and pharmaceutical companies. Clinical teams used it to produce care plans and patient notes in real time, reducing time spent on documentation and allowing more focus on decision-making and patient care. Predictive AI was applied to flag potential hospital readmissions and other risks before they materialised, contributing to efficiency gains and better patient outcomes. At the same time, AI-generated, multi-language patient education materials helped address gaps in communication, particularly for underserved populations.

In the pharmaceutical and healthcare marketing sectors, data intelligence and targeting technologies helped refine how companies engaged with both clinicians and patients. Rather than relying on broad messaging, marketers used AI-driven insights to tailor communications more precisely, increasing engagement and improving return on investment.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Device Authority addresses security risks as AI takes control of physical machines

Device Authority's KeyScaler platform supports secure AI-driven automation by helping organisations authenticate connected machines, protect device identities and control access to physical equipment.

Talking Medicines examines factors influencing prescribing decisions

Talking Medicines explains how healthcare professional conversations, clinical considerations and treatment perceptions can provide pharmaceutical companies with deeper insight into prescribing intent beyond traditional campaign metrics.

What HCPs say could reveal prescribing intent

Talking Medicines is using AI to analyse HCP conversations and identify the clinical and practical factors that may influence prescribing intent.

AI control of machines raises new security questions

AI is gaining the ability to control physical equipment, but establishing that machines are genuine, authorised and secure will be an important part of making this technology safe to deploy.

CAR-T therapy brings new approach to multiple myeloma treatment

CAR-T therapy is being used in multiple myeloma and is being studied earlier in the treatment pathway, with research focused on improving durability, safety and access.

Tern cuts H1 loss by 60% as portfolio growth and funding strengthen

Tern reduced its first-half loss by 60%, with net asset value improving and further fundraising strengthening the balance sheet. Additional funding has supported Talking Medicines and Device Authority, while continued progress across the portfolio provides further scope for value creation.

Search